It looks like someone already posted an update, but I'll report what I was told. The S-1 was amended due to a SEC request for more detailed information to be added to the previous August filing. Amy said that the company has ample cash to finish all phase II trials into next June. Partnership discussions, both domestically and internationally, are still underway, and there is continuing interest from multiple would be partners. New 2013 milestones should be available to investors soon regarding neopulse, and 2013 should see aggressive clinical application and success. All of which should be reflected by a growing price per share. Partnership would still likely require dilution, so all of those discussing a partnership fall through doomsday scenario are clearly misinformed. GLTA.
Investor's still spooked over recent S-1/A They need to come over here and read these posts. Amy confirmed my hunch today. I believe they have a partner lined up. That's why they can raise the ante from 10 mil to 20 mil max offering. In due time they will dilute , after they obtain a partner.
Amy alluded that if there was additional financing, it would be for 10-15 million at the most. Possibly hinting at partner aid in financing, or some shares being used for partner equity purposes. This is merely speculation, however, in my opinion this bodes well for the future.